Fulgent Genetics officer to sell 939 shares for taxes

Fulgent Genetics, Inc. (FLGT) is the issuer for a Rule 144 notice filed for the account of Hanlin Gao, an officer.

Rhea-AI Filing Summary

Fulgent Genetics, Inc. (FLGT) is the issuer for a Rule 144 notice filed for the account of Hanlin Gao, an officer. The notice covers a proposed sale of 939 shares of common stock through Morgan Stanley Smith Barney LLC. These shares relate to equity compensation, including restricted stock/RSUs that vested on February 26, 2024, from which 21,146 shares were acquired.

The filer also reports prior sales in the last three months of 945 shares and 1,688 shares of FLGT common stock. According to the statement, the current proposed sale and recent sales were executed as "sell to cover" transactions to satisfy tax withholding obligations tied to RSU vesting, and are described as not representing discretionary trades by the reporting person.

Key Figures

Shares to be sold: 939 shares Aggregate market value of shares to be sold: $18,691.05 Shares outstanding: 27,515,293 shares +5 more

8 metrics

Shares to be sold 939 shares Common stock proposed to be sold under Rule 144 through Morgan Stanley Smith Barney LLC

Aggregate market value of shares to be sold $18,691.05 Value associated with the 939 FLGT shares covered by the notice

Shares outstanding 27,515,293 shares Common stock outstanding of Fulgent Genetics, Inc. used in the Rule 144 computation

Shares acquired from restricted stock vesting 21,146 shares Equity compensation for services rendered on February 26, 2024

Shares sold on May 27, 2026 945 shares Common stock sale reported in the past three months section

Proceeds from May 27, 2026 sale $16,631.98 Aggregate value for 945 shares sold

Shares sold on June 2, 2026 1,688 shares Common stock sale reported in the past three months section

Proceeds from June 2, 2026 sale $30,190.71 Aggregate value for 1,688 shares sold

Key Terms

Rule 144, Restricted Stock Units, sell to cover, restricted stock vest

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"Shares sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"were made to satisfy tax withholding obligations through "sell to cover" transactions"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

restricted stock vest financial

"Restricted stock vest | Fulgent Genetics, Inc."

A restricted stock vest is the moment when shares granted to an employee or executive under conditions (like staying at the company or hitting targets) officially become theirs to keep or sell. Think of it as a timed gift that unlocks only after certain rules are met. Investors watch vesting because it can change who controls shares, create potential selling pressure when large blocks unlock, and reveal how management’s incentives are aligned with company performance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for FLGT disclose about Hanlin Gao's planned sale?

The notice states that 939 shares of Fulgent Genetics, Inc. (FLGT) common stock may be sold through Morgan Stanley Smith Barney LLC. The shares are tied to equity compensation and are associated with restricted stock/RSU vesting on February 26, 2024.

How many FLGT shares did Hanlin Gao acquire from equity compensation?

The filing reports that 21,146 shares of Fulgent Genetics, Inc. common stock were acquired on February 26, 2024 through restricted stock vesting as equity compensation for services rendered.

What FLGT share sales has Hanlin Gao made in the past three months?

The notice lists two sales of Fulgent Genetics (FLGT) common stock in the past three months: 945 shares on May 27, 2026 for $16,631.98 and 1,688 shares on June 2, 2026 for $30,190.71.

Why were the recent FLGT share sales by Hanlin Gao executed?

The filing explains that the proposed sale and the past three months’ sales were completed to cover tax withholding obligations in connection with the vesting of Restricted Stock Units, using "sell to cover" transactions, and are described as not being discretionary trades by the reporting person.

How many FLGT shares are reported as outstanding in the Form 144 notice?

The document lists 27,515,293 shares of Fulgent Genetics, Inc. common stock as outstanding for purposes of the Rule 144 computation. This figure provides context for the relative size of the reported transactions.

What is the aggregate market value of the FLGT shares covered by the Form 144?

For the planned sale of 939 shares of Fulgent Genetics, Inc. common stock, the Form 144 reports an aggregate market value of $18,691.05.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 09:00 AM EDT Accepted by SEC EDGAR 08/27/2026 - 08:33 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001684532
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	FULGENT GENETICS, INC.
SEC File Number	001-37894
Address of Issuer	4399 Santa Anita Ave El Monte CALIFORNIA 91731
Phone	626-350-0537
Name of Person for Whose Account the Securities are To Be Sold	Gao Hanlin
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004	939	18691.05	27515293	08/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/26/2024	Restricted stock vest	Fulgent Genetics, Inc.			21146	02/26/2024	Equity compensation for services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Hanlin Gao C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	05/27/2026	945	16631.98
Hanlin Gao C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	06/02/2026	1688	30190.71

144: Remarks and Signature

Remarks	Shares sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale, along with sales during the past 3 months, were made to satisfy tax withholding obligations through "sell to cover" transactions and do not represent a discretionary trade by the reporting person.
Date of Notice	08/27/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Paul Kim as Attorney-In-Fact
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)